It's in the Genes: Health Care ETF Outperforms the S&P 500

The Ark Genomic Revolution ETF (ARC G) focuses on companies in the genomics industry, bridging healthcare and technology. It primarily includes biotech, healthcare services, and pharmaceuticals. The fund holds around 40 companies, such as Illumina and Bristol Myers Squibb, involved in advancements like targeted therapeutics and CRISPR. The genomics industry is valued over $15 billion, with an annual growth forecast of 8.5% until 2025. ARC G has outperformed the S&P 500 since its launch, managing $430 million in assets with a 0.75% expense ratio. It is actively managed and rated positively by Bloomberg Intelligence.

What industries does the Ark Genomic Revolution ETF primarily target?

What types of advancements do the companies held by the Ark Genomic Revolution ETF focus on?

What is the estimated worth of the global genomics industry?

How has the performance of the Ark Genomic Revolution ETF compared to the S&P 500?

What is the expense ratio of the Ark Genomic Revolution ETF?